Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gram-negative sepsis. Background, clinical features, and intervention.

R C Bone1

  • 1Department of Internal Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago.

Chest
|September 1, 1991
PubMed
Summary

Gram-negative sepsis is a critical condition affecting over 200,000 people annually in the US. Monoclonal antibodies targeting endotoxin show promise in preventing septic shock and reducing mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

JAMA·2001
Same author

T-cell reactivity and its predictive role in immunosuppression after burns.

Critical care medicine·1999
Same author

To SIRS with love.

Critical care medicine·1998
Same author

Radiographic patterns of pulmonary disease.

Current problems in diagnostic radiology·1997
Same author

Important new findings in sepsis.

JAMA·1997
Same author

Sepsis: a new hypothesis for pathogenesis of the disease process.

Chest·1997

Area of Science:

  • Medical Microbiology
  • Immunology
  • Critical Care Medicine

Background:

  • Gram-negative sepsis presents a significant public health challenge with high mortality rates (20-50%).
  • The concept of sepsis syndrome aids in identifying early, preshock states to facilitate timely intervention.
  • Understanding endotoxin's role in Gram-negative bacterial infections is crucial for developing effective treatments.

Purpose of the Study:

  • To review early clinical and metabolic indicators of sepsis syndrome.
  • To examine current therapeutic strategies for Gram-negative sepsis.
  • To explore novel biotechnological approaches for sepsis treatment, focusing on endotoxin neutralization.

Main Methods:

  • Literature review of clinical indicators and current therapies for sepsis.
  • Discussion of the pathophysiology of endotoxin release from Gram-negative bacteria.
  • Evaluation of emerging biotechnological treatments, including monoclonal antibodies.

Main Results:

  • Early identification of sepsis syndrome indicators is vital for prognosis.
  • Current therapies for sepsis are under continuous review and improvement.
  • Monoclonal antibodies against endotoxin demonstrate significant potential in preclinical studies.

Conclusions:

  • Monoclonal antibodies offer a promising avenue to mitigate sepsis progression to shock.
  • Targeting endotoxin can potentially reduce sepsis-related mortality and economic burden.
  • Continued research into novel treatments is essential for combating Gram-negative sepsis.

Related Experiment Videos